The cardiologist's role in the management of type 2 diabetes-a review

Carrie Eshelbrenner, Karina Vasquez, Liberty O. Yanze, Rene A Oliveros, Robert J Chilton

Research output: Contribution to journalArticle

Abstract

Evidence-based medicine is key to the cardiologist's role in the management of type 2 diabetes. Proven therapies that reduce cardiovascular (CV) events with few off-target effects are imperative. Evidence from epidemiology studies supports the concept that increased blood sugar is correlated with increased CV events. Unfortunately, the lowering of glucose with current agents shows limited benefit in reducing CV events. Metformin in the obese individual reduced CV events and is currently first-line therapy in most clinical practice guidelines. Recently, a meta-analysis reported that current hypoglycemic agents did not improve CV outcomes and were possibly harmful. Possible exceptions come from the Prospective pioglitazone clinical trial in macrovascular events (PROactive), a secondary prevention trial in patients with prior myocardial infarction in which pioglitazone was found to reduce CV events. Glucagon-like peptide-1 (GLP-1) agonists appear to be the most exciting new CV agents, but a dipeptidyl peptidase-4 (DPP4) inhibitor (sitagliptin) combined with a high-dose angiotensin-converting enzyme inhibitor (ACEI) (enalapril) may increase blood pressure and heart rate. Lifestyle modification and proven global risk reduction are still the number one ways to reduce CV events in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)26-29
Number of pages4
JournalUS Cardiology
Volume9
Issue number1
StatePublished - Feb 2012

Fingerprint

pioglitazone
Type 2 Diabetes Mellitus
Dipeptidyl-Peptidase IV Inhibitors
Cardiovascular Agents
Enalapril
Glucagon-Like Peptide 1
Metformin
Evidence-Based Medicine
Risk Reduction Behavior
Secondary Prevention
Practice Guidelines
Angiotensin-Converting Enzyme Inhibitors
Hypoglycemic Agents
Blood Glucose
Meta-Analysis
Life Style
Epidemiology
Heart Rate
Myocardial Infarction
Clinical Trials

Keywords

  • Dipeptidyl peptidase-4 inhibitors
  • Exenatide
  • Glucagon-like peptide-1
  • Hypertension
  • Hypoglycemia
  • Pioglitazone
  • Sitagliptin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Eshelbrenner, C., Vasquez, K., Yanze, L. O., Oliveros, R. A., & Chilton, R. J. (2012). The cardiologist's role in the management of type 2 diabetes-a review. US Cardiology, 9(1), 26-29.

The cardiologist's role in the management of type 2 diabetes-a review. / Eshelbrenner, Carrie; Vasquez, Karina; Yanze, Liberty O.; Oliveros, Rene A; Chilton, Robert J.

In: US Cardiology, Vol. 9, No. 1, 02.2012, p. 26-29.

Research output: Contribution to journalArticle

Eshelbrenner, C, Vasquez, K, Yanze, LO, Oliveros, RA & Chilton, RJ 2012, 'The cardiologist's role in the management of type 2 diabetes-a review', US Cardiology, vol. 9, no. 1, pp. 26-29.
Eshelbrenner C, Vasquez K, Yanze LO, Oliveros RA, Chilton RJ. The cardiologist's role in the management of type 2 diabetes-a review. US Cardiology. 2012 Feb;9(1):26-29.
Eshelbrenner, Carrie ; Vasquez, Karina ; Yanze, Liberty O. ; Oliveros, Rene A ; Chilton, Robert J. / The cardiologist's role in the management of type 2 diabetes-a review. In: US Cardiology. 2012 ; Vol. 9, No. 1. pp. 26-29.
@article{025e3b72cce64833bca6e5fa901be783,
title = "The cardiologist's role in the management of type 2 diabetes-a review",
abstract = "Evidence-based medicine is key to the cardiologist's role in the management of type 2 diabetes. Proven therapies that reduce cardiovascular (CV) events with few off-target effects are imperative. Evidence from epidemiology studies supports the concept that increased blood sugar is correlated with increased CV events. Unfortunately, the lowering of glucose with current agents shows limited benefit in reducing CV events. Metformin in the obese individual reduced CV events and is currently first-line therapy in most clinical practice guidelines. Recently, a meta-analysis reported that current hypoglycemic agents did not improve CV outcomes and were possibly harmful. Possible exceptions come from the Prospective pioglitazone clinical trial in macrovascular events (PROactive), a secondary prevention trial in patients with prior myocardial infarction in which pioglitazone was found to reduce CV events. Glucagon-like peptide-1 (GLP-1) agonists appear to be the most exciting new CV agents, but a dipeptidyl peptidase-4 (DPP4) inhibitor (sitagliptin) combined with a high-dose angiotensin-converting enzyme inhibitor (ACEI) (enalapril) may increase blood pressure and heart rate. Lifestyle modification and proven global risk reduction are still the number one ways to reduce CV events in type 2 diabetes.",
keywords = "Dipeptidyl peptidase-4 inhibitors, Exenatide, Glucagon-like peptide-1, Hypertension, Hypoglycemia, Pioglitazone, Sitagliptin",
author = "Carrie Eshelbrenner and Karina Vasquez and Yanze, {Liberty O.} and Oliveros, {Rene A} and Chilton, {Robert J}",
year = "2012",
month = "2",
language = "English (US)",
volume = "9",
pages = "26--29",
journal = "US Cardiology Review",
issn = "1758-3896",
publisher = "Touch Briefings",
number = "1",

}

TY - JOUR

T1 - The cardiologist's role in the management of type 2 diabetes-a review

AU - Eshelbrenner, Carrie

AU - Vasquez, Karina

AU - Yanze, Liberty O.

AU - Oliveros, Rene A

AU - Chilton, Robert J

PY - 2012/2

Y1 - 2012/2

N2 - Evidence-based medicine is key to the cardiologist's role in the management of type 2 diabetes. Proven therapies that reduce cardiovascular (CV) events with few off-target effects are imperative. Evidence from epidemiology studies supports the concept that increased blood sugar is correlated with increased CV events. Unfortunately, the lowering of glucose with current agents shows limited benefit in reducing CV events. Metformin in the obese individual reduced CV events and is currently first-line therapy in most clinical practice guidelines. Recently, a meta-analysis reported that current hypoglycemic agents did not improve CV outcomes and were possibly harmful. Possible exceptions come from the Prospective pioglitazone clinical trial in macrovascular events (PROactive), a secondary prevention trial in patients with prior myocardial infarction in which pioglitazone was found to reduce CV events. Glucagon-like peptide-1 (GLP-1) agonists appear to be the most exciting new CV agents, but a dipeptidyl peptidase-4 (DPP4) inhibitor (sitagliptin) combined with a high-dose angiotensin-converting enzyme inhibitor (ACEI) (enalapril) may increase blood pressure and heart rate. Lifestyle modification and proven global risk reduction are still the number one ways to reduce CV events in type 2 diabetes.

AB - Evidence-based medicine is key to the cardiologist's role in the management of type 2 diabetes. Proven therapies that reduce cardiovascular (CV) events with few off-target effects are imperative. Evidence from epidemiology studies supports the concept that increased blood sugar is correlated with increased CV events. Unfortunately, the lowering of glucose with current agents shows limited benefit in reducing CV events. Metformin in the obese individual reduced CV events and is currently first-line therapy in most clinical practice guidelines. Recently, a meta-analysis reported that current hypoglycemic agents did not improve CV outcomes and were possibly harmful. Possible exceptions come from the Prospective pioglitazone clinical trial in macrovascular events (PROactive), a secondary prevention trial in patients with prior myocardial infarction in which pioglitazone was found to reduce CV events. Glucagon-like peptide-1 (GLP-1) agonists appear to be the most exciting new CV agents, but a dipeptidyl peptidase-4 (DPP4) inhibitor (sitagliptin) combined with a high-dose angiotensin-converting enzyme inhibitor (ACEI) (enalapril) may increase blood pressure and heart rate. Lifestyle modification and proven global risk reduction are still the number one ways to reduce CV events in type 2 diabetes.

KW - Dipeptidyl peptidase-4 inhibitors

KW - Exenatide

KW - Glucagon-like peptide-1

KW - Hypertension

KW - Hypoglycemia

KW - Pioglitazone

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84866772390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866772390&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84866772390

VL - 9

SP - 26

EP - 29

JO - US Cardiology Review

JF - US Cardiology Review

SN - 1758-3896

IS - 1

ER -